PRESS RELEASE published on 03/04/2025 at 08:35, 10 months 27 days ago AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch AB Science's masitinib and its phase 3 principal investigator, neurologist Patrick Vermersch, featured in Life Sciences Magazine for potential breakthrough in Progressive MS Treatment AB Science Masitinib Patrick Vermersch Life Sciences Magazine Progressive MS Treatment
BRIEF published on 01/29/2025 at 19:08, 1 year ago AB Science Updates on Masitinib Platform Progress Multiple Sclerosis Masitinib Platform ALS Study Alzheimer’s Treatment AB Science Strategy
PRESS RELEASE published on 01/29/2025 at 19:03, 1 year ago AB Science today provides an update on its masitinib platform AB Science provides update on masitinib platform for ALS, MS, and AD. Positive results show potential for huge market sales. Debt negotiation planned Update AB Science Masitinib Platform Market Sales Debt Negotiation
BRIEF published on 01/24/2025 at 18:06, 1 year ago AB Science to Present Masitinib Update in Upcoming Webcast Pharmaceuticals Webcast Research Update AB Science Masitinib
PRESS RELEASE published on 01/24/2025 at 18:01, 1 year ago AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET AB Science to host live webcast on masitinib platform update on January 28, 2025, 5.30pm CET. Leading pharmaceutical company specializing in protein kinase inhibitors Pharmaceutical Company Live Webcast AB Science Protein Kinase Inhibitors Masitinib Platform
BRIEF published on 01/22/2025 at 19:04, 1 year ago AB Science Participates in Biomed Forum Investors Conference Investor Conference BIOMED Forum AB Science Masitinib Protein Kinase Inhibitors
PRESS RELEASE published on 01/22/2025 at 18:59, 1 year ago AB Science will participate in the Biomed Forum investors conference AB Science to participate in Biomed Forum Investors Conference organized by AllInvest Securities in Paris on February 4, 2025 Pharmaceutical Company BIOMED Forum AB Science Investors Conference AllInvest Securities
BRIEF published on 12/17/2024 at 19:09, 1 year 1 month ago AB Science presents the advances of AB8939 for acute myeloid leukemia Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
PRESS RELEASE published on 12/17/2024 at 19:04, 1 year 1 month ago AB Science provides a summary of the webcast held on December 16, 2024 AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum Market Potential AML Treatment AB Science Phase 1 AB8939
BRIEF published on 10/17/2024 at 19:33, 1 year 3 months ago AB Science Faces Setback in EMA Approval for ALS Treatment AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
Published on 01/31/2026 at 03:15, 13 hours 12 minutes ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 14 hours 7 minutes ago Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 14 hours 47 minutes ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 17 hours 27 minutes ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 15:54, 32 minutes ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 4 hours 2 minutes ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 13 hours 42 minutes ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 18 hours 27 minutes ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 20 hours 17 minutes ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 17:45, 22 hours 42 minutes ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 1 day 22 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 22 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 22 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
